Pfizer, Sanofi-Aventis, Eli Lilly: Emerging Markets Earnings Roundup (Part 3 of 3)
• By PharmAsia News
A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources from Europe and the U.S. to Asia and seeking partnerships in those geographies. Analysts boosted earnings per share numbers to companies that disclosed detailed emerging markets sales data, such as AstraZeneca, which started the trend in Q1, and Pfizer as the first American pharma to break out emerging market sales by product. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.